| First Author | Nielsen LL | Year | 1995 |
| Journal | Anticancer Res | Volume | 15 |
| Issue | 2 | Pages | 385-92 |
| PubMed ID | 7763010 | Mgi Jnum | J:46464 |
| Mgi Id | MGI:1199241 | Citation | Nielsen LL, et al. (1995) In wap-ras transgenic mice, tumor phenotype but not cyclophosphamide-sensitivity is affected by genetic background. Anticancer Res 15(2):385-92 |
| abstractText | Male wap-ras transgenic mice develop adenocarcinomas in salivary and/or mammary tissue by age 1 year. When the wap-ras transgene was bred into the FVB/N strain, males developed multiple mammary tumors between 1.5 and 3 mo. of age, but no salivary tumors. Crosses between ras/FVB mice and other strains produced moderate changes in mammary tumor onset and severity, but no salivary tumors. Histopathological analysis of 62 adenocarcinomas from 18 mice yielded: 14 tumors with areas of squamous metaplasia, many tumors with epithelium-lined cysts, few immune cells in tumors, and no lung metastases. Cyclophosphamide delayed tumor onset and inhibited the growth of established tumors. Our results suggest that wap-ras mice will be useful for studying ras-mediated tumor genetics and should be a good assay system for both preventative and curative anticancer therapies. |
